Express News | Kanglong Chemical: Currently, we have not seen the impact of the Biomedicine Act on customer acquisition

Breakings14:43

Tiger Pharmaceuticals (300347): Short-term demand under pressure is expected to improve to drive a recovery in performance

Guide to this report: The company released its 2024 quarterly report. The performance was slightly lower than expected. The performance declined due to the base effect and weakening order demand. It is expected that the 24-year results will pick up quarterly as demand improves. Key investment points: maintaining “increasing holdings”

國泰君安13:51

Hangzhou Tigermed Consulting Co., Ltd Just Missed Earnings - But Analysts Have Updated Their Models

As you might know, Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) last week released its latest first-quarter, and things did not turn out so great for shareholders. The analysts look to hav

Simply Wall St08:45

Asymchem Laboratories (Tianjin) Co., Ltd. Recorded A 25% Miss On Revenue: Analysts Are Revisiting Their Models

It's been a good week for Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) shareholders, because the company has just released its latest first-quarter results, and the shares gained 5.7% to CN

Simply Wall St08:43

Express News | The latest 10 billion private equity positions revealed! Deng Xiaofeng and Feng Liu move frequently

Breakings08:03

Kanglong Chemical (300759): Overseas front-end R&D demand is picking up, and profit margins are expected to improve quarterly

The 2024Q1 results are in line with our expectations for 2024Q1: revenue of 2,671 billion yuan, -2.0% YoY; net profit to mother of 231 million yuan, -33.8% YoY; operating cash flow 7.46

中金公司Apr 27 16:46